Leuven · Pre-Seed–Series B · 13 people tracked
Investment thesis
Droia invests globally and exclusively in therapeutics companies focused on oncology and genetic disease. It targets young drug development firms whose technology platforms or scientific insights address previously unsolvable clinical problems and translate innovation into clinical breakthroughs. As hands-on investors and entrepreneurs with an in-house team of drug development experts, Droia supports companies from creation through clinical proof of concept, often taking interim roles and building companies from the ground up. Through Droia Labs, its scientific arm, the firm validates novel ideas and provides state-of-the-art facilities. Success is measured in patient benefit relative to the severity of unmet medical need and improvement over standard of care.
Source: firm website, verified Aug 7, 2026.
Team · 13 people
from curated & public directories
What they invest in
from 27 of 29 portfolio companiesBiotech ×27Healthtech ×16Medical Devices ×9Deep Tech ×8AI & Machine Learning ×6Digital Health ×2Longevity ×2
HQs:United States×14Belgium×2Netherlands×1
Who they back
founder profiles across 13 portfolio companiesFounding team size:solo founder×42 founders×63 founders×24+ founders×1
Investments · 29 tracked
founders shown can be your intro pathBy year:2025 · 42024 · 22022 · 12021 · 22019 · 110 dated
Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors.
BiotechHealthtechMedical DevicesCambridge, US
Elisabet de los Pinos, Ph.D.(Executive Officer, Director)Elisabet de los Pinos(Founder)inMichael Wyzga(Executive Officer)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)Lewis Geffen(Executive Officer)
Co-investorsAdvent Life SciencesChiesi VenturesForesite CapitalJazzya InvestmentsMedicxiMyelin VC+4 more
Hyku Biosciences develops small molecule therapeutics with novel mechanisms of action designed to covalently bind non-cysteine amino acids and inactivate disease-driving proteins.
BiotechDeep TechMedical DevicesBurlington, US
KLEEM CHAUDHARY(Executive Officer, Director, Promoter)Ku-Lung (Ken) Hsu, PhD(Endowed Associate Professor of Chemistry)Kleem Chaudhary, PhD(President & CEO)
BoardJOHN GUSTOFSON(Director)LAURA BRASS(Director)inLAURA TADVALKAR(Director)
Board seatJanwillem NaesensMatthias Van Woensel· per SEC Form D
Co-investorsEisai Innovation, Inc.Novartis Venture FundRA Capital
Judo Bio develops oligonucleotide medicines, including ligand-siRNA conjugate drugs, delivered to the kidney for systemic and renal diseases using its STRIKE (Selectively Targeting RNA Into KidnEy) platform.
BiotechHealthtechCambridge, US
Andrew Fraley(Co-founder)inAlfica SehgalinOMMER CHOHAN(Executive Officer)JAMES JEFFREY GOATER(Executive Officer, Director)Simon Read(CEO)inWilliam Ho
Co-investorsAtlas VentureDigitalis VenturesThe Column GroupYK Bioventures
Montis Biosciences develops anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome and a second CD93 program in lung squamous cell carcinoma.
BiotechHealthtechLeuven, BE
Federico Grossi(Clinical Advisor & Acting CMO)
Co-investorsPfizer VenturesVIBPfizer Venture Investments
Vico Therapeutics develops targeted genetic medicines for neurological disorders, with a focus on antisense oligonucleotide therapies designed to address the underlying genetic causes of diseases like Huntington's disease and spinocerebellar ataxias.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
Luc Dochez(Chair and Founder)Josh Mandel-Brehm(Co-Founder)
Co-investorsKurma PartnersPureos BioventuresEQT Life SciencesSeroba Life SciencesEurazeoIdinvest Partners
Montis Biosciences is a biotechnology company developing anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome.
BiotechHealthtechLeuven, BE
Federico Grossi(Clinical Advisor & Acting CMO)
Co-investorsPfizer VenturesVIBPfizer Venture Investments
Volastra Therapeutics is a drug discovery and development company working on novel cancer therapies.
BiotechHealthtechNew York, US
Samuel Bakhoum(Co-Founder & Chief Scientific Officer)inLewis Cantley(Founder and Chair of Scientific Advisory Committee)Olivier Elemento(Founder and Scientific Advisor)David P. Southwell(Chief Executive Officer)in
BoardRobert Mittendorff(Director)Jill Goldstein(Director)
Co-investorsARCH Venture PartnersB Capital GroupB4 CapitalVida Ventures
Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.
BiotechDeep TechMedical DevicesEindhoven, US
Christian Ottmann(Executive Officer)inJosh Seidenfeld(Executive Officer)Michelle Arkin(Director)Nancy Pryer(Executive Officer)Margarita Chavez(Director)Bryan Miller(Executive Officer)
Board seatJanwillem Naesens· per SEC Form D
Co-investorsMission BiocapitalMRL Ventures FundNextech InvestInkefRA Capital
QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.
BiotechDeep TechMedical DevicesCambridge, US
Kevin Eggan(Co-founder)inRoet(Co-founder)Woolf(Co-founder)Kasper Roet(Director, Executive Officer, Promoter)inShafique Virani(Executive Officer)inJason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)in
Board seatLuc Dochez· per SEC Form D
Co-investorsMC Healthcare VenturesMission BiocapitalMitsui Global InvestmentSanofi VenturesSV Health InvestorsAmgen Ventures+6 more
BiotechSomerville, US
Adarsha Koirala(Executive Officer, Director)Gerald Sewack(Director)Reza Halse(Director)
Board seatLuc Dochez· per SEC Form D · $64.5M raise · filed Apr 2022
Accent Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs to improve health outcomes for cancer patients.
BiotechHealthtechLongevity
Co-investorsAtlas VentureEcoR1 CapitalGV (Google Ventures)The Column GroupJJDCJohnson & Johnson Innovation – JJDC+1 more
Actio is a precision medicine company developing therapeutics by leveraging genetic insights to treat rare diseases and common conditions at their molecular root.
AI & Machine LearningBiotech
Alesta Therapeutics develops therapies for rare diseases, with research focused on genetic diseases and oncology.
BiotechHealthtech
Ilan Ganot(CEO)Benit Maru(CMO)Matthias Van Woensel(CSO)
Co-investorsFrazier Life SciencesNovartis Venture FundFrazier Healthcare PartnersRTW Investments L.P.Thuja Capital
Arcus Biosciences develops combination cancer therapies, producing small molecules and antibodies designed to be combined and advanced from Phase 1 studies through commercialization.
Biotech
Juan Jaen(Founder)in
Co-investorsAisling CapitalDecheng CapitalEcoR1 CapitalForesite CapitalSLVCSofinnova Ventures+2 more
Cristal Therapeutics develops therapeutics in the life sciences sector.
BiotechDeep TechDigital HealthMedical DevicesUtrecht, NL
Dr. Cristianne Rijcken(Chief Scientific Officer and Founder)Dr. Joost Holthuis(Co-founder and former CEO)
Co-investorsBioGeneration VenturesChemelot VenturesThuja CapitalBOM
Cyteir is a clinical-stage oncology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters.
BiotechHealthtechCambridge, US
Kevin Mills(Executive Officer, Director)inRonald Goldstein(Executive Officer)inDonald Corcoran(Executive Officer, Director)inMarkus Renschler(Director)in
BoardTimothy Romberger(Director)Barry Mills(Director)
Co-investorsLightstone VenturesOUP (Osage University Partners)
Frontier is a drug discovery company developing small-molecule covalent drugs aimed at previously undruggable protein targets across the proteome.
AI & Machine LearningBiotechSouth San Francisco, US
Chris Varma, Ph.D.(Executive Officer, Director)Chris Varma(Co-founder, Chairman and CEO)inJim Winkler(Executive Officer)Johannes Hermann, Ph.D.(Executive Officer)Kevin Webster(Executive Officer)inGregory Chow(Executive Officer)
Co-investorsBerkeley CatalystDCVC (Data Collective)MPM BioImpactRA CapitalDCVC BioDeerfield Management Company
Highlight Therapeutics is a biotech company developing therapeutic treatments.
BiotechHealthtech
Marisol Quintero(Chief Operating Officer (former CEO 2013-2025))in
Co-investorsColumbus Venture Partners
Hillstar Bio develops precision immunotherapies for autoimmune diseases, using antibody engineering to selectively deplete pathogenic immune cells while sparing healthy ones.
BiotechHealthtech
Co-investorsFrazier Life SciencesLifeArc Ventures
Hummingbird Bioscience is a precision biotherapeutics company developing a pipeline of novel targeted therapies for cancer, using proprietary drug discovery technologies and platforms.
AI & Machine LearningBiotechDeep TechHealthtech
Piers Ingram(Chief Executive Officer, Co-Founder, Executive Director)Jerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)Konrad Paszkiewicz(Chief Technology Officer)Kwek Kon Yew(Chief Medical Officer)Dipti Thakkar(Chief Operating Officer)in
Co-investorsAltium CapitalClavystBioDecheng CapitalFrazier Life SciencesKiwoom InvestmentMuirwoods Ventures+2 more
Mahzi develops therapies for patients with under-diagnosed and under-served rare genetic neurodevelopmental disorders, working with patient and family groups, academic researchers, and industry partners.
BiotechHealthtechSouth San Francisco, US
Yael Weiss(Executive Officer, Director)in
BoardCamille Samuels(Director)inMarten Steen(Director)inShalini Sharp(Director)inStephen Farr(Director)
Co-investorsHealthCapMitsui Global InvestmentVenrockVenrock Associates
Muna Therapeutics is a biotechnology company that discovers and develops therapies aimed at slowing or stopping neurodegenerative diseases, including Alzheimer's and Parkinson's.
BiotechLongevity
Rita Balice-Gordon(Founder)in
Co-investorsSanofi VenturesSofinnova PartnersV-Bio Ventures
Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones.
AI & Machine LearningBiotechDeep TechDigital HealthSan Diego, US
Co-investorsNovartis Venture FundDigitalis VenturesForbionLightspeed Venture PartnersMPM BioImpactVida Ventures+1 more
BiotechHealthtechSan Diego, US
Brent J. Warner(Executive Officer, Director)inXIN JIANG(President & CEO)inHANK MICHAEL PETRASSI(Executive Officer)JEFFERY KELLY(Director)
BoardTIM LOHOFF(Director)Edward Hurwitz(Director)
Co-investorsDigitalis VenturesForbionLightspeed Venture PartnersMPM BioImpactNovartis Venture FundVida Ventures+1 more
Santa Monica, US
Michael Einziger(Executive Officer, Director)Edna Coryell(Executive Officer, Director)Katherine Power(Director)Jessica Goldin(Executive Officer, Director)
BoardAnn Marie Simpson(Director)
Co-investors8VCFrazier Life SciencesNovartis Venture FundRTW Investments L.P.The Column GroupThuja Capital+1 more
Unnatural Products is a drug discovery platform company that develops synthetic macrocycles to target previously undruggable disease targets.
AI & Machine LearningBiotechDeep TechMedical DevicesSanta Cruz, US
Cameron Pye(Co-Founder & CEO)inJoshua Schwochert(Co-Founder & CSO)in
BoardVasudev Bailey(Director)in
Co-investorsAbstract VenturesArtis VenturesAsset Management CompanyBetter Ventures Central LlcBlue Bear VenturesFirst Spark Ventures, Llc+6 more
Vaderis develops a first-of-its-kind oral therapy for hereditary hemorrhagic telangiectasia (HHT), a rare vascular disease with no existing approved treatments.
BiotechHealthtechMedical Devices
Co-investorsMedicxi
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 1
IPOs and acquisitions across the tracked portfolioAura BiosciencesNASDAQ: AURA
Portfolio news
latest coverage across their companies
Arcus Biosciences · pluang.com · Aug 19, 2026
Alesta · axios.com · Aug 18, 2026
Aura Biosciences · tickerreport.com · Aug 18, 2026
Mahzi Therapeutics · forbes.com · Jul 13, 2026
Protego · finsmes.com · Apr 23, 2026
Quralis · nasdaqprivatemarket.com · Apr 3, 2026
Protego Biopharma · xtalks.com · Jan 8, 2026
Frequently asked questions
- How many investments has Droia Ventures made?
- Droia Ventures has 24 tracked investments, including 2 dated in the last 24 months.
- What stage does Droia Ventures invest at?
- Droia Ventures invests at the Pre-Seed, Seed, Series A, Series B stages.
- What is Droia Ventures's typical check size?
- Droia Ventures typically writes checks of $540K.
- What sectors does Droia Ventures focus on?
- Droia Ventures focuses on Biotech, Healthtech.
- Where is Droia Ventures located?
- Droia Ventures is headquartered in Leuven, BE.
- Does Droia Ventures lead rounds?
- Droia Ventures typically participates in rounds rather than leading them.
- Who does Droia Ventures co-invest with?
- Droia Ventures most often shares deals with Frazier Life Sciences, Novartis Venture Fund, Foresite Capital, among 63 tracked co-investors.
Images
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Khosla Ventures is a venture capital firm founded by Vinod Khosla.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
Lux Capital is a venture capital firm that backs founders building transformative deep technologies, having been among the first investors in category-defining companies across AI, robotics, biotech, defense, and infrastructure.